AB
CARM

Amalgamated Bank’s Carisma Therapeutics CARM Stock Holding History

Amalgamated Bank’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-899
Closed -$2K – 3026
2024
Q1 		$2K Sell
899
-1,427
-61% -$3.43K ﹤0.01% 2874
2023
Q4 		$7K Sell
2,326
-268
-10% -$797 ﹤0.01% 2907
2023
Q3 		$11K Hold
2,594
– – ﹤0.01% 2874
2023
Q2 		$23K Buy
+2,594
New +$14.1K ﹤0.01% 2671
2022
Q2 		– Sell
-1,639
Closed -$20K – 3054
2022
Q1 		$20K Sell
1,639
-121
-7% -$1.69K ﹤0.01% 2807
2021
Q4 		$29K Buy
1,760
+128
+8% +$2.58K ﹤0.01% 2133
2021
Q3 		$26K Buy
1,632
+18
+1% +$864 ﹤0.01% 2156
2021
Q2 		$149K Buy
+1,614
New +$103K ﹤0.01% 2069

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amalgamated Bank's CARM Position: Q2 2024 in Review

Amalgamated Bank sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 899 shares — an estimated $2K sold.

Amalgamated Bank first reported a position in CARM in Q2 2021 and held it in 8 quarters. The position peaked at $149K in Q2 2021. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

  • Amalgamated Bank reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Amalgamated Bank sold 899 Carisma Therapeutics shares in Q2 2024, an estimated $2K.
  • Amalgamated Bank first reported a position in Carisma Therapeutics in Q2 2021 and held it in 8 quarters.
  • Amalgamated Bank's Carisma Therapeutics position peaked at $149K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on Amalgamated Bank's 13F filing for Q2 2024, filed 12 Aug 2024.